EP3288549A1 - Oral liquid compositions of guanfacine - Google Patents

Oral liquid compositions of guanfacine

Info

Publication number
EP3288549A1
EP3288549A1 EP16789380.9A EP16789380A EP3288549A1 EP 3288549 A1 EP3288549 A1 EP 3288549A1 EP 16789380 A EP16789380 A EP 16789380A EP 3288549 A1 EP3288549 A1 EP 3288549A1
Authority
EP
European Patent Office
Prior art keywords
guanfacine
liquid composition
oral liquid
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16789380.9A
Other languages
German (de)
French (fr)
Other versions
EP3288549A4 (en
Inventor
Romi Barat Singh
Kalaiselvan Ramaraju
Balaram Mondal
Ashish Kumar
Suchitra Kaushik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2015/053209 external-priority patent/WO2015166473A1/en
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of EP3288549A1 publication Critical patent/EP3288549A1/en
Publication of EP3288549A4 publication Critical patent/EP3288549A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A61J1/1418—Threaded type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2027—Separating means having frangible parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2814—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it
    • B65D51/2828—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being a film or a foil
    • B65D51/2835—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being a film or a foil ruptured by a sharp element, e.g. a cutter or a piercer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3205—Separate rigid or semi-rigid containers joined to each other at their external surfaces
    • B65D81/3211—Separate rigid or semi-rigid containers joined to each other at their external surfaces coaxially and provided with means facilitating admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2401/00—Tamper-indicating means
    • B65D2401/15—Tearable part of the closure
    • B65D2401/25—Non-metallic tear-off strips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2401/00—Tamper-indicating means
    • B65D2401/50—Tamper-band co-operating with intermediate ring connected to the container

Definitions

  • the present invention relates to oral liquid compositions of guanfacine.
  • the liquid compositions can be immediate release or extended release compositions.
  • the compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition.
  • the liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.
  • Guanfacine is a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. It is also indicated is indicated in the management of hypertension, either alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
  • AdHD Attention Deficit Hyperactivity Disorder
  • Guanfacine hydrochloride a pharmaceutically acceptable salt of guanfacine, is a white to off-white crystalline powder, sparingly soluble in water (approximately 1 mg/mL) and alcohol and slightly soluble in acetone.
  • the chemical designation for guanfacine hydrochloride is N-amidino-2-(2,6-dichlorophenyl)- acetamide monohydrochloride. The chemical structure is:
  • U.S. Patent No. 5,854,290 discloses the method of treating a behavioral disinhibition (e.g. Attention-Deficit Hyperactivity Disorder) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
  • a behavioral disinhibition e.g. Attention-Deficit Hyperactivity Disorder
  • U.S. Patent No.'s 6,287,599 and 6,811,794 describe sustained release tablet compositions of guanfacine, comprising at least one non-pH dependent sustained release agent; and at least one pH dependent agent that increases the rate of release of guanfacine from the tablet at a pH in excess of 5.5.
  • Guanfacine is presently marketed only in solid dosage forms i.e. immediate release and extended release tablets for oral administration.
  • solid dosage forms are not suitable for some patients who have difficulty in swallowing solid dosage forms e.g. pediatric patients or incapacitated patients. Further, solid dosage forms may not be convenient, when chronic therapy is needed. Therefore, there exists a clear need in the art for oral liquid compositions of guanfacine.
  • a prime concern with any liquid formulation is the stability of the active ingredient, both short term and over the time.
  • Inventors of the present application have for the first time developed oral liquid compositions of guanfacine.
  • the compositions are stable both during manufacturing and shelf life.
  • Said liquid compositions are suitable for both immediate release and extended release of guanfacine.
  • the present invention is a significant advance over the available solid dosage forms of guanfacine and fulfills the long felt need to improve patient compliance by providing an oral liquid composition of guanfacine with acceptable stability.
  • Oral liquid compositions of guanfacine also offer additional advantages as they are easy to manufacture with functional reproducibility.
  • the oral liquid compositions described herein are provided with a pleasant mouth feel thereby further enhancing patient compliance and ease of administration.
  • the present invention relates to oral liquid compositions of guanfacine.
  • the compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition.
  • Said liquid compositions are stable, in that, the amount of impurity 2, 6-dichlorophenyl acetic acid in the composition is within the prescribed limits to the extent necessary for the sale and use of the composition .
  • compositions are in the form of ready-to-use compositions or reconstituted liquid compositions.
  • the compositions can be immediate release compositions or extended release compositions. Said compositions offer better patient compliance and dosing flexibility based on age and body weight of the patients. It also relates to processes for the preparation of said oral liquid compositions.
  • a first aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
  • a second aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition comprises guanfacine in a concentration from about 0.1 mg/rtiL to about 12.0 mg/mL of the composition.
  • the composition comprises guanfacine in a concentration from about 1.0 mg/mL to about 7.0 mg/mL of the composition.
  • a third aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a stable composition.
  • the composition is stable for at least seven days. More particularly, the composition is stable for at least one month or further, to the extent necessary for the sale and use of the composition.
  • the composition comprises less than about 1.0% w/w of 2, 6-dichlorophenyl acetic acid. Particularly, the composition comprises less than about 0.7% w/w of 2, 6-dichlorophenyl acetic acid.
  • the composition comprises less than about 3.0% w/w of total related substances. Particularly, the composition comprises less than about 2.0% w/w of total related substances.
  • a fourth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition has a pH of less than about 6.8.
  • the composition is a taste- masked composition.
  • a fifth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a ready-to-use liquid composition or a reconstituted liquid composition.
  • the ready-to-use liquid composition comprises a solution, a suspension, a syrup, a concentrate, an elixir or an emulsion.
  • the reconstituted liquid composition comprises a solution and/or a suspension reconstituted from powder comprising granules, pellets, or beads.
  • a sixth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an immediate release form.
  • guanfacine is present as powder, pellets, granules or beads, as guanfacine-resin complex, or as inert cores coated with guanfacine.
  • a seventh aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an extended release form.
  • the composition comprises:
  • guanfacine may be present in the core or layered over an inert particle to form a core.
  • release-controlling agent may be present in the core or coated over the guanfacine core or both.
  • the release-controlling agent is selected from the group comprising a pH-dependent release-controlling agent, a pH-independent release- controlling agent or mixtures thereof.
  • the core further comprises one or more pharmaceutically acceptable excipients selected from the group comprising acids, osmogents, binders, glidants, or combinations thereof.
  • the carrier comprises one or more of liquid adjuvants and other pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients in the carrier are selected from the group comprising acids, osmogents, buffering agents, suspending agents, glidants, sweetening agents, flavors, colorants, anti-caking agents, wetting agents, preservatives, antioxidants, chelating agents, binders, viscosity modifiers, and combinations thereof.
  • An eighth aspect of the present invention provides a method of treating Attention Deficit Hyperactivity Disorder or Hypertension by administering an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
  • the oral liquid composition is administered once daily.
  • guanfacine refers to guanfacine, as well as its pharmaceutically acceptable salts, polymorphs, hydrates, solvates, prodrugs, chelates, and complexes.
  • exemplary salts include salts of inorganic or organic acids such as hydrochloride, hydrobromide, sulphate, sulfamate, nitrate, phosphate, formate, mesylate, citrate, benzoate, fumarate, maleate, tartrate, and succinate.
  • a particularly preferred salt of guanfacine is guanfacine hydrochloride.
  • the oral liquid composition comprises guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition.
  • the oral liquid composition comprises guanfacine in a concentration from about 1.0 mg/mL to about 7.0 mg/mL of the composition.
  • Guanfacine particularly guanfacine hydrochloride, is found to degrade at high pH values. Solution state stability studies have indicated that at 16 hours, assay values of guanfacine have dropped down to 86.3% and 84% at pH 6.8 and 7.5 respectively and even further reduced at 24 hours.
  • One of the major impurity of guanfacine is 2, 6- dichlorophenyl acetic acid.
  • the pH of the reconstituted liquid composition or ready-to-use liquid composition implies pH values measured for the pharmaceutically acceptable carrier, for the coated cores, or in the microen vironment of guanfacine, or combination of these that is sufficient to prevent degradation of guanfacine.
  • stable refers to chemical stability, wherein the amount of impurity 2, 6- dichlorophenyl acetic acid in the composition remains less than about 1.0% w/w, particularly less than about 0.7% w/w upon storage of the composition for a period of at least seven days, more particularly, for a period of at least one month, or further, to the extent necessary for the sale and use of the composition.
  • the "liquid composition,” includes ready-to-use liquid composition or reconstituted liquid composition.
  • the ready-to-use liquid composition comprises a solution, a suspension, a syrup, a concentrate, an elixir or an emulsion or like.
  • the reconstituted liquid compositions comprises solution and/or suspension reconstituted from dry powder comprising pellets, granules, beads or the like.
  • Guanfacine may be present in the above compositions in immediate release form, extended release form or combinati on of both.
  • immediate release implies that guanfacine is released from the composition in an immediate release fashion and does not involve delayed release or extended release, but may include taste-masking.
  • guanfacine When present in immediate release form, guanfacine may be present as powder, pellets, granules or beads. In one example, guanfacine, either alone or mixed with one or more of routinely used pharmaceutically acceptable excipients may be dissolved or dispersed in the pharmaceutically acceptable carrier.
  • guanfacine may be present as a resin complex that provides immediate release of guanfacine upon administration of the composition. These guanfacine -resin complexes are then dispersed in the pharmaceutically acceptable carrier as defined above.
  • Cation- and amon-exehange resins are well-known in the art. Few exemplary resins that can be used according to the invention include, but are not limited to, Dowex ® resins and others made by Dow Chemical; Amberlite ® , Amberlyst ® and other resins made by Rohm and Haas; Indion ® resins made by Ion Exchange, Ltd.
  • guanfacine may be present as coating over inert cores. These coated cores, optionally mixed with one or more pharmaceutically acceptable excipients are dispersed in a pharmaceutically acceptable carrier.
  • the guanfacine coated core may be further optionally coated with a coating layer comprising a film-forming agent to mask the bitter taste or to improve the stability. The coating layer prevents guanfacine release during storage, but is quickly penetrated by gastric fluid allowing rapid release of guanfacine.
  • the film- forming agent can be a water-soluble polymer in which the release of guanfacine is prevented by using a high molar concentration of the solutes in the reconstituted composition, wherein the solutes have a higher affinity towards water.
  • the high molar concentration of the solutes generates hypertonic conditions leading to high osmolality and thus prevents the leaching of the guanfacine from the coated cores.
  • the film-forming agent can have a pll dependent solubility in which the release of active ingredient is prevented by using a pre-adjusted pH of the reconstituted composition such that the film-forming agent does not get dissolved in the reconstituted composition but get dissolved when exposed to the physiological conditions.
  • inert particle refers to a particle made from a sugar sphere also known as a non-pareil seed, a microcrystalline cellulose sphere, a dibasic calcium phosphate bead, a mannitol bead, a silica bead, a tartaric acid pellet, a wax based pellet, and the like.
  • Extended release are used to define a release profile to effect delivery of guanfacine over an extended period of time, as being between about 60 minutes to about 2, 4, 6, 8, 12 or 24 hours. Extended release includes sustained release, controlled release, multiphase release, delayed release, pulsatile release, chrono release and the like.
  • composition When present in an extended release form, the composition comprises:
  • the cores may comprise guanfacine as powder, granules, and pellets.
  • guanfacine may be layered over an inert particle to form a core.
  • guanfacine may be present as a complex with a suitable complexing agent such as cyclodextrin, ion-exchange resins.
  • the core is in the form of a bead, pellet, granule, and spheroid or like.
  • the release-controlling agent is selected from the group comprising a pH- dependent release-controlling agent, a pH-independent release-controlling agent or mixtures thereof.
  • pH-dependent release-controlling agents are selected from the group comprising acrylic copolymers such as methacrylic acid and methyl methacrylate copolymers, e.g., Eudragit ® L 100 and Eudragit ® S 100, methacrylic acid and ethyl acrylate copolymers, e.g., Eudragit ® L 100-55 and Eudragit ® L 30 D-55, dimethylaminoethyl methacrylate and butyl methacrylate and methyl methacrylate copolymers e.g., Eudragit ® E 100, Eudragit ® E PO, methyl acrylate and methacrylic acid and octyl acrylate copolymers, styrene and acrylic acid copolymers, butyl acrylate and styrene and acrylic acid copolymers, and ethylacrylate-methacrylic acid copolymer;
  • acrylic copolymers such as methacrylic
  • cellulose acetate phthalate cellulose acetate succinates
  • hydroxyalkyl cellulose phthalates such as hydroxypropylmethyl cellulose phthalate
  • hydroxyalkyl cellulose acetate succinates such as hydroxypropylmethyl cellulose acetate succinate
  • vinyl acetate phthalates vinyl acetate succinate
  • cellulose acetate trimelliate polyvinyl derivatives such as polyvinyl acetate phthalate, polyvinyl alcohol phthalate, polyvinyl butylate phthalate, and polyvinyl acetoacetal phthalate
  • zein shellac
  • mixtures thereof such as polyvinyl acetate phthalate, polyvinyl alcohol phthalate, polyvinyl butylate phthalate, and polyvinyl acetoacetal phthalate
  • pH-independent release-controlling agents ar e selected from the group comprising cellulosic polymers such as ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and carboxy methylcellulose; acrylic copolymers such as methacrylic acid copolymers, e.g., Eudragit ® RS, Eudragit ® RL, Eudragit ® NE 30 D;; polyethylene derivatives e.g., polyethylene glycol and polyethylene oxide; polyvinyl alcohol; polyvinyl acetate; gums e.g., guar gum, locust bean gum, tragacanth, carrageenan, alginic acid, gum acacia, gum arabic, gellan gum, and xanthan gum; triglycerides; waxes, e.g., Compritol
  • the coating additives used in the present invention are selected from the group comprising plasticizers, opacifiers, anti-tacking agents, coloring agents, or combinations thereof.
  • Suitable plasticizers are selected from the group comprising triethyl citrate, dibutylsebacate, triacetin, acetylated triacetin, tributyl citrate, glyceryl tributyrate, diacetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyl oxalate, diethyl phthalate, diethyl malate, diethyl fumarate, dibutyl succinate, diethyl malonate, dioctyl phthalate, and mixtures thereof.
  • Suitable opacifiers are selected from the group comprising titanium dioxide, manganese dioxide, iron oxide, silicon dioxide, and mixtures thereof.
  • Suitable anti-tacking agents are selected from the group comprising talc, magnesium stearate, calcium stearate, stearic acid, silica, glyceryl monostearate, and mixtures thereof.
  • Suitable coloring agents are selected from the group consisting of FD&C (Federal Food, Drug and Cosmetic Act) approved coloring agents; natural coloring agents; natural juice concentrates; pigments such as iron oxide, titanium dioxide, and zinc oxide; and mixtures thereof.
  • FD&C Food, Drug and Cosmetic Act
  • Suitable solvents used for granulation or for forming a solution or dispersion for coating are selected from the group comprising water, ethanol, methylene chloride, isopropyl alcohol, acetone, methanol, and combinations thereof.
  • the diameter of the cores comprising guanfacine and a release-controlling agent has a ds>o value of less than about 1.5 mm. More particularly, dgo value is less than 1.2 mm. It is desirable to keep the diame ter of the cores within the specified size so as to avoid sedimentation of the cores, grittiness in the mouth and thereby rendering the composition more acceptable.
  • the diameter of the cores is measured according to known methods, such as using Camsizer.
  • the term "dw value,” means at least 90% of the cores have volume diameter in the specified range when measured by a suitable method, for example, Camsizer.
  • composition constitutes the liquid part of the composition and comprises one or more of liquid adjuvants and other pharmaceutically acceptable excipients.
  • suitable liquid adjuvants comprise water. It may optionally comprise a co-solvent, for example, propylene glycol, glycerol, sorbitol, and the like, to assist solubilization and incorporation of various water-insoluble ingredients, such as flavoring oils and the like, into the composition.
  • other pharmaceutically acceptable excipients in the carrier are selected from the group comprising acids, osmogents, buffering agents, suspending agents, glidants, sweetening agents, flavors, colorants, anti-caking agents, wetting agents, preservatives, antioxidants, chelating agents, binders, viscosity modifiers, emulsifiers, and combinations thereof.
  • Suitable acids are selected from the group comprising organic acids, inorganic acids or mixtures thereof.
  • Organic acids are selected from the group comprising citric acid, fumaric acid, tartaric acid, oxalic acid, succinic acid, adipic acid, phthalic acid, acetic acid, alginic acid, ascorbic acid, aspartic acid, benzoic acid, cyclamic acid, erythorbic acid, glutamic acid hydrochloride, lactic acid, maleic acid, methacrylic acid, oleic acid, palmitic acid, sorbic acid, stearic acid, and combinations thereof.
  • Inorganic acids are selected from the group comprising hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, perchloric acid, and combinations thereof.
  • Citric acid, fumaric acid, tartaric acid, ascorbic acid, benzoic acid, and hydr ochloric acid are preferably used.
  • osmogents refers to all pharmaceutically acceptable inert water-soluble compounds that can imbibe or dissolve in water and/or aqueous biological fluids.
  • Suitable examples of osmogents or pharmaceutically acceptable inert water-soluble compounds are selected from the group comprising carbohydrates such as xylitol, mannitol, sorbitol, arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, dextrose and raffmose; water-soluble salts of inorganic acids such as magnesium chloride, magnesium sulfate, potassium sulfate, lithium chloride, sodium chloride, potassium chloride, lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydr ogen phosphate, lithium dihydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, and sodium phosphate tribasic; water-soluble salts of
  • the osmogents used in the present invention are xylitol, mannitol, glucose, lactose, sucrose, and sodium chloride.
  • the osmogents used in the present invention are xylitol, mannitol, glucose, lactose, sucrose, and sodium chloride.
  • Suitable buffering agents are selected from the group comprising hydrochloric acid, citric acid, sodium citrate, potassium citrate, acetate buffer, sodium acetate trihydrate, potassium dihydrogen orthophosphate, trisodium hydrogen orthophosphate, sodium dihydrogen orthophosphate, disodium hydrogen orthophosphate, and mixtures thereof.
  • Suitable suspending agents are selected from the group comprising cellulose derivatives such as co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose and its salts/derivatives, and microcrystalline cellulose; carbomers; gums such as locust bean gum, xanthan gum, tragacanth gum, arabinogalactan gum, agar gum, gellan gum, guar gum, apricot gum, karaya gum, sterculia gum, acacia gum, gum arabic, and carrageenan; pectin; dextran; gelatin; polyethylene glycols; polyvinyl compounds such as polyvinyl acetate, polyvinyl alcohol, and polyvinyl pyrrolidone; sugar alcohols such as xylitol and mannitol; colloidal silica; and mixtures thereof.
  • the co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium have been marketed under the trade names Avicel ® RC-501, Avicel ® RC-581, Avicel ® RC-591, and Avicel ® CL-611.
  • Suitable glidants are selected from the group comprising silica, calcium silicate, magnesium silicate, colloidal silicon dioxide, corn starch, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, hydrogenated vegetable, and mixtures thereof.
  • Suitable sweetening agents are selected from the group comprising saccharine or its salts such as sodium, potassium, or calcium, cyclamate or its salt, aspartame, alitame, acesulfame or its salt, stevioside, glycyrrhizin or its derivatives, sucralose, and mixtures thereof.
  • Suitable flavors are selected from the group comprising peppermint, grapefruit, orange, lime, lemon, mandarin, pineapple, strawberry, raspberry, mango, passion fruit, kiwi, apple, pear, peach, apricot, cherry, grape, banana, cranberry, blueberry, black currant, red currant, gooseberry, lingon berries, cumin, thyme, basil, camille, valerian, fennel, parsley, chamomile, tarragon, lavender, dill, bargamot, salvia, aloe vera balsam, spearmint, eucalyptus, and combinations thereof.
  • Suitable coloring agents are selected from the group comprising dyes, natural coloring agents or pigments, approved for use under Federal Food, Drug and Cosmetic Act.
  • Suitable anti-caking agents are selected from the group comprising colloidal silicon dioxide, tribasic calcium phosphate, powdered cellulose, magnesium trisilicate, starch, and mixtures thereof.
  • Suitable wetting agents are selected from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, and combinations thereof.
  • Suitable examples of wetting agents are sodium lauryl sulphate; cetrimide; polyethylene glycols;
  • polyoxyethylene-polyoxypropylene block copolymers such as poloxamers; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid esters such as sorbitan monostearate; polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate; polyethylene glycol fatty acid ester such as polyoxyethylene monostear ate; polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil; and mixtures thereof.
  • Suitable preservatives are selected from the group comprising parabens such as methyl, ethyl, propyl, and butyl p-hydroxybenzoic acid esters, alkyl hydroxybenzoates, sorbic acid or a salt thereof, benzoic acid or a salt thereof, salts of edetate (also known as salts of ethylenediaminetetraacetic acid or EDTA, such as disodium edetate), benzalkonium chloride, and mixtures thereof.
  • parabens such as methyl, ethyl, propyl, and butyl p-hydroxybenzoic acid esters, alkyl hydroxybenzoates, sorbic acid or a salt thereof, benzoic acid or a salt thereof, salts of edetate (also known as salts of ethylenediaminetetraacetic acid or EDTA, such as disodium edetate), benzalkonium chloride, and mixtures thereof.
  • parabens such
  • Suitable antioxidants are selected from the group comprising butylated hydroxytoluene (BUT), butylated hydroxyanisole (BHA), sodium metabisulfite, ascorbic acid, propyl gallate, thiourea, tocopherols, beta-carotene, and mixtures thereof.
  • Suitable chelating agents are selected from the group comprising ethylenediamine tetraacetic acid (EDTA) and its salts, such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, and mixtures thereof.
  • EDTA ethylenediamine tetraacetic acid
  • salts such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, and mixtures thereof.
  • Suitable binders are selected from the group comprising polyvinyl pyrrolidone, starch, pregelatinized starch, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, gums, acrylate polymers, and mixtures thereof.
  • Suitable viscosity modifiers are selected from the group comprising chitosan, acacia, alginic acid bentonite, carbomers, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethyl cellulose, glycerin, gelatin guar gum, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, any other suitable cellulose-based component, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, starch, sodium starch glycolate, starch tragacanth, xanthan gum, and mixtures thereof.
  • Suitable emulsifiers include, but are not limited to natural emulsifier, an anionic emulsifier or a nonionic emulsifier. These include, but are not limited to, sodium dodecyl sulfate, sodium octadecyl sulfate, sorbitol anhydrate, tween, and mixtures thereof.
  • the viscosity of the pharmaceutically acceptable carrier ranges from about 300 cps to about 15,000 cps. Preferably, the viscosity of the carrier ranges from about 500 cps to about 10,000 cps, More preferably, the viscosity of the carrier ranges from about 500 cps to about 7,000 cps.
  • the viscosity of the carrier of the present invention is measured by using a Brookfield Viscometer having a # 3 spindle rotating at 20 rpm at 25 °C.
  • the liquid composition When the liquid composition is an extended release composition, it may additionally comprise an immediate release component for biphasic or pulsatile type of release. Immediate release component may help in providing an immediate therapeutic effect which could be subsequently followed by an extended therapeutic effect over a longer duration of time.
  • immediate release component may be present in the form a powder, pellets, beads, spheroids or granules of guanfacine in the carrier.
  • the immediate release component may be present in the form of an immediate release coating of guanfacine over the extended release coated cores.
  • the immediate release component of guanfacine may be present in form of guanfacine-resin complexes.
  • the invention also provides for methods of making the compositions described herein by usual methods well known in the art.
  • Ready-to use liquid compositions may be prepared by the conventional processes comprising dissolving an amount of guanfacine and any other excipients into the pharmaceutically acceptable carrier.
  • the process comprises preparing cores comprising guanfacine and optionally one or more other pharmaceutically acceptable excipients. These guanfacine containing cores are then coated with a suitable polymer for immediate release or extended release by usual coating techniques. These coated cores are then dispersed in the pharmaceutically acceptable carrier to form ready-to-use liquid composition.
  • Reconstituted liquid compositions of the present invention may be prepared by the process comprising the steps of forming powder, granules or pellets as dry powder by conventional processes.
  • the process also includes forming complexes of guanfacine with ion-exchange resins, compri sing loading a plurality of resin particles with guanfacine to form drug-resin particles. These particles may optionally be further coated with immediate release or extended release coating using conventional techniques. Methods of loading drugs onto resin particles are generally known in the art.
  • the ready-to-use liquid compositions of the present invention may be packaged in a suitable package such as a bottle.
  • the dry powder for reconstitution may be packaged in a suitable package such as a bottle or a sachet.
  • the sachet can be filled as a unit dose or a multi dose sachet.
  • the present invention further includes a co-package or a kit comprising two components, wherein one package or one component comprises a dry powder and another package or another component comprises the pharmaceutically acceptable carrier.
  • a twin chamber pack with two chambers can be used. In this case, one chamber comprises a powder for suspension and another chamber comprises the carrier.
  • the invention also provides for various methods of treatment using the compositions described herein.
  • the invention provides for methods of treating ADHD or hypertension comprising administering an effective amount of any of the composition described herein, wherein the composition is meant for immediate release or extended release or combination of both.
  • the invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
  • compositions prepared as per Example 1 and Example 2 were stored at room temperature and the samples were analyzed after 3 days and 7 days. Stability results are represented in Table 2 below. Table 2: Stability data of compositions prepared as per Example 1 and Example 2
  • Examples 3-5 Compositions of guanfacine with different acids
  • Guanfacine hydrochloride Guanfacine hydrochloride, suitable acid (fumaiic/tartaric/citric acids) were mixed in water to form liquid compositions.
  • compositions prepared as per Examples 3-5 were stored at room temperature and the samples were analyzed after 30 days. Stability results are represented in Table 3 below. Table 3- Stability data of compositions prepared as per Examples 3-5
  • Citric acid, mannitol, hydroxypropylmethyl cellulose, guanfacine hydrochloride were dissolved in purified water. 2. Microcrystalline cellulose spheres were coated with the solution of step 1.
  • Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
  • step 4 The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
  • Microcrystalline cellulose - sodium carboxymethyl cellulose, xanthan gum, colloidal silicon dioxide, sucralose, xylitol, strawberry flavor, citric acid, methyl/ propyl paraben (if present) were mixed in purified water to form the pharmaceutically acceptable carrier.
  • the extended release powder for suspension compositions prepared as per Examples 7 and 8 were stored at 40°C/ 75%RH for 3 months and 1 month respectively. Thereafter, the powder for suspension was reconstituted with the carrier and the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The initial levels of impurities/ related substances and levels after 3 months/ 1 month are represented in Table 4 below.
  • the extended release powder for suspension prepared as per Examples 6 and 8 was reconstituted with the carrier and the in-vitro dissolution was determined for 4 mg dose at day 0 using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C.
  • the results of the release studies are represented in Table 5.
  • Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
  • step 4 The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
  • the extended release powder for suspension was reconstituted with the pharmaceutically acceptable carrier and packed in a suitable container.
  • compositions prepared as per Examples 9-12 were stored at room temperature for 30 days. After 30 days, the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The results are represented in Table 6 below.
  • the powder for suspension compositions prepared as per Examples 9-1 1 was stored for 10 days/ 30 days. After 10 days/ 30 days, the in-vitro dissolution was determined for 4 mg dose using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C. The results of the release studies are represented in Table 7 below. Table 7- Percentage (%) of guanfacine release from reconstituted liquid compositions prepared as per Examples 9-11 in hydrochloric acid buffer pH 2.2, USP type II, 75 rpm, 900ml
  • Citric acid, mannitol, hydroxypropyl methylcellulose, guanfacine hydrochloride were dissolved in purified water.
  • step 4 The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
  • Microcrystalline cellulose - sodium carboxymethyl cellulose, xylitol, citric acid, xanthan gum, colloidal silicon dioxide, sucralose, strawberry flavor, methyl paraben and propyl paraben were mixed in purified water to form the pharmaceutically acceptable carrier.
  • the extended release powder for suspension composition prepared as per Example 14 was stored at 40°C/75%RH for one month. After one month, the powder for suspension was reconstituted with the carrier and the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The initial levels of impurities/ related substances and levels after 1 month are represented in Table 8 below.
  • the extended release powder for suspension prepared as per Example 14 was stored at 40°C/75%RH for one month. After one month, the in-vitro dissolution was determined for 4 mg dose using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C. The results of the initial release studies and after 1 month are represented in Table 9 below.
  • Table 9 Percentage (%) of guanfacine release from extended release powder for suspension prepared as per Example 14 in 900mL of hydrochloric acid buffer, pH 2.2. USP type II. 75 rpm
  • Viscosity of the carrier prepared as per Example 14 was measured by Brookfield viscometer. The values are provided in Table 11 below. Table 11: Viscosity measurements
  • Citric acid, Eudragit ® L 100-55, triethyl citrate, talc, guanfacine hydrochloride were dispersed in a mixture of acetone and purified water.
  • Microcrystalline cellulose spheres were coated with the dispersion of step 1.
  • Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
  • step 4 The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
  • Microcrystalline cellulose - sodium carboxymethyl cellulose, xylitol, citric acid, xanthan gum, colloidal silicon dioxide, sucralose, strawberry flavor, methyl paraben and propyl paraben were mixed in purified water to form the pharmaceutically acceptable carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL, to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.

Description

ORAL LIQUID COMPOSITIONS OF GUANFACINE
Field of the Invention
The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.
Background of the Invention
Guanfacine is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. It is also indicated is indicated in the management of hypertension, either alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Guanfacine hydrochloride, a pharmaceutically acceptable salt of guanfacine, is a white to off-white crystalline powder, sparingly soluble in water (approximately 1 mg/mL) and alcohol and slightly soluble in acetone. The chemical designation for guanfacine hydrochloride is N-amidino-2-(2,6-dichlorophenyl)- acetamide monohydrochloride. The chemical structure is:
Guanfacine and its pharmaceutically acceptable salts is disclosed in U.S. Patent No. 3,632,645. U.S. Patent No. 5,854,290 discloses the method of treating a behavioral disinhibition (e.g. Attention-Deficit Hyperactivity Disorder) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
U.S. Patent No.'s 6,287,599 and 6,811,794 describe sustained release tablet compositions of guanfacine, comprising at least one non-pH dependent sustained release agent; and at least one pH dependent agent that increases the rate of release of guanfacine from the tablet at a pH in excess of 5.5. Guanfacine is presently marketed only in solid dosage forms i.e. immediate release and extended release tablets for oral administration. However, solid dosage forms are not suitable for some patients who have difficulty in swallowing solid dosage forms e.g. pediatric patients or incapacitated patients. Further, solid dosage forms may not be convenient, when chronic therapy is needed. Therefore, there exists a clear need in the art for oral liquid compositions of guanfacine. To date, no liquid compositions of guanfacine are known. The only FDA approved guanfacine products are solid dosage forms i.e. tablets. In view of this, liquid compositions of guanfacine are desirable over presently available solid dosage forms, as they would offer better patient compliance, convenience and flexible dosing regimen.
However, a prime concern with any liquid formulation is the stability of the active ingredient, both short term and over the time. Inventors of the present application have for the first time developed oral liquid compositions of guanfacine. The compositions are stable both during manufacturing and shelf life. Said liquid compositions are suitable for both immediate release and extended release of guanfacine.
Therefore, the present invention is a significant advance over the available solid dosage forms of guanfacine and fulfills the long felt need to improve patient compliance by providing an oral liquid composition of guanfacine with acceptable stability.
Oral liquid compositions of guanfacine also offer additional advantages as they are easy to manufacture with functional reproducibility. The oral liquid compositions described herein are provided with a pleasant mouth feel thereby further enhancing patient compliance and ease of administration.
Summary of the Invention
The present invention relates to oral liquid compositions of guanfacine. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. Said liquid compositions are stable, in that, the amount of impurity 2, 6-dichlorophenyl acetic acid in the composition is within the prescribed limits to the extent necessary for the sale and use of the composition .
The compositions are in the form of ready-to-use compositions or reconstituted liquid compositions. The compositions can be immediate release compositions or extended release compositions. Said compositions offer better patient compliance and dosing flexibility based on age and body weight of the patients. It also relates to processes for the preparation of said oral liquid compositions.
Detailed Description of the Invention
A first aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
A second aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition comprises guanfacine in a concentration from about 0.1 mg/rtiL to about 12.0 mg/mL of the composition. Particularly, the composition comprises guanfacine in a concentration from about 1.0 mg/mL to about 7.0 mg/mL of the composition.
A third aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a stable composition. Particularly, the composition is stable for at least seven days. More particularly, the composition is stable for at least one month or further, to the extent necessary for the sale and use of the composition.
According to one embodiment, the composition comprises less than about 1.0% w/w of 2, 6-dichlorophenyl acetic acid. Particularly, the composition comprises less than about 0.7% w/w of 2, 6-dichlorophenyl acetic acid.
According to another embodiment, the composition comprises less than about 3.0% w/w of total related substances. Particularly, the composition comprises less than about 2.0% w/w of total related substances.
A fourth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition has a pH of less than about 6.8.
According to another embodiment of the above aspects, the composition is a taste- masked composition.
A fifth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a ready-to-use liquid composition or a reconstituted liquid composition.
According to another embodiment, the ready-to-use liquid composition comprises a solution, a suspension, a syrup, a concentrate, an elixir or an emulsion. According to another embodiment, the reconstituted liquid composition comprises a solution and/or a suspension reconstituted from powder comprising granules, pellets, or beads.
A sixth aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an immediate release form.
In above embodiments, guanfacine is present as powder, pellets, granules or beads, as guanfacine-resin complex, or as inert cores coated with guanfacine.
A seventh aspect of the present invention provides an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an extended release form.
In an embodiment of the above, the composition comprises:
(i) cores comprising guanfacine and a release-controlling agent; and
(ii) a pharmaceutically acceptable carrier.
In one embodiment, guanfacine may be present in the core or layered over an inert particle to form a core.
In another embodiment, release-controlling agent may be present in the core or coated over the guanfacine core or both.
In another embodiment, the release-controlling agent is selected from the group comprising a pH-dependent release-controlling agent, a pH-independent release- controlling agent or mixtures thereof.
In another embodiment, the core further comprises one or more pharmaceutically acceptable excipients selected from the group comprising acids, osmogents, binders, glidants, or combinations thereof.
In another embodiment, the carrier comprises one or more of liquid adjuvants and other pharmaceutically acceptable excipients.
In another embodiment, the pharmaceutically acceptable excipients in the carrier are selected from the group comprising acids, osmogents, buffering agents, suspending agents, glidants, sweetening agents, flavors, colorants, anti-caking agents, wetting agents, preservatives, antioxidants, chelating agents, binders, viscosity modifiers, and combinations thereof.
An eighth aspect of the present invention provides a method of treating Attention Deficit Hyperactivity Disorder or Hypertension by administering an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
In an embodiment of the above aspect, the oral liquid composition is administered once daily.
The term "guanfacine", as used herein, refers to guanfacine, as well as its pharmaceutically acceptable salts, polymorphs, hydrates, solvates, prodrugs, chelates, and complexes. Exemplary salts include salts of inorganic or organic acids such as hydrochloride, hydrobromide, sulphate, sulfamate, nitrate, phosphate, formate, mesylate, citrate, benzoate, fumarate, maleate, tartrate, and succinate. A particularly preferred salt of guanfacine is guanfacine hydrochloride.
The oral liquid composition comprises guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. Preferably, the oral liquid composition comprises guanfacine in a concentration from about 1.0 mg/mL to about 7.0 mg/mL of the composition.
Guanfacine, particularly guanfacine hydrochloride, is found to degrade at high pH values. Solution state stability studies have indicated that at 16 hours, assay values of guanfacine have dropped down to 86.3% and 84% at pH 6.8 and 7.5 respectively and even further reduced at 24 hours. One of the major impurity of guanfacine is 2, 6- dichlorophenyl acetic acid.
Inventors have surprisingly discovered that degradation of guanfacine can be prevented by maintaining the pll of the composition to less than about 6.8. In the present invention, the pH of the reconstituted liquid composition or ready-to-use liquid composition implies pH values measured for the pharmaceutically acceptable carrier, for the coated cores, or in the microen vironment of guanfacine, or combination of these that is sufficient to prevent degradation of guanfacine.
The term "stable," as used herein, refers to chemical stability, wherein the amount of impurity 2, 6- dichlorophenyl acetic acid in the composition remains less than about 1.0% w/w, particularly less than about 0.7% w/w upon storage of the composition for a period of at least seven days, more particularly, for a period of at least one month, or further, to the extent necessary for the sale and use of the composition.
The "liquid composition," includes ready-to-use liquid composition or reconstituted liquid composition. The ready-to-use liquid composition comprises a solution, a suspension, a syrup, a concentrate, an elixir or an emulsion or like. The reconstituted liquid compositions comprises solution and/or suspension reconstituted from dry powder comprising pellets, granules, beads or the like.
Guanfacine may be present in the above compositions in immediate release form, extended release form or combinati on of both.
As used herein, the term "immediate release," implies that guanfacine is released from the composition in an immediate release fashion and does not involve delayed release or extended release, but may include taste-masking.
When present in immediate release form, guanfacine may be present as powder, pellets, granules or beads. In one example, guanfacine, either alone or mixed with one or more of routinely used pharmaceutically acceptable excipients may be dissolved or dispersed in the pharmaceutically acceptable carrier.
In another example, guanfacine may be present as a resin complex that provides immediate release of guanfacine upon administration of the composition. These guanfacine -resin complexes are then dispersed in the pharmaceutically acceptable carrier as defined above. Cation- and amon-exehange resins are well-known in the art. Few exemplary resins that can be used according to the invention include, but are not limited to, Dowex® resins and others made by Dow Chemical; Amberlite®, Amberlyst® and other resins made by Rohm and Haas; Indion® resins made by Ion Exchange, Ltd. (India), Diaion® resins by Mitsubishi; Type AG® and other resins by BioRad; Sephadex® and Sepharose® made by Amersham; resins by Lewatit, sold by Fluka; Toyopearl® resins by Toyo Soda; IONAC® and Whatman® resins sold by VWR; and BakerBond resins sold by J T Baker; hydrophilic colloids such as, alginate, chitosan, carboxymethylcellulose, croscarmellose, microcrystalline cellulose, xanthan gum; carboxy vinyl polymers such as carbomer 94, polylysine, gelatin; and resins having polymer backbones comprising styrene-divinyl benzene copolymers and having pendant ammonium or tetraalkyl ammonium functional groups, available from Rohm and Haas, sold under the trade name DUOLITE™ AP143; or any combinations thereof. Alternatively, guanfacine may be present as coating over inert cores. These coated cores, optionally mixed with one or more pharmaceutically acceptable excipients are dispersed in a pharmaceutically acceptable carrier. The guanfacine coated core may be further optionally coated with a coating layer comprising a film-forming agent to mask the bitter taste or to improve the stability. The coating layer prevents guanfacine release during storage, but is quickly penetrated by gastric fluid allowing rapid release of guanfacine. In one example, the film- forming agent can be a water-soluble polymer in which the release of guanfacine is prevented by using a high molar concentration of the solutes in the reconstituted composition, wherein the solutes have a higher affinity towards water. The high molar concentration of the solutes generates hypertonic conditions leading to high osmolality and thus prevents the leaching of the guanfacine from the coated cores. Further, the film-forming agent can have a pll dependent solubility in which the release of active ingredient is prevented by using a pre-adjusted pH of the reconstituted composition such that the film-forming agent does not get dissolved in the reconstituted composition but get dissolved when exposed to the physiological conditions.
The term "inert particle," as used herein, refers to a particle made from a sugar sphere also known as a non-pareil seed, a microcrystalline cellulose sphere, a dibasic calcium phosphate bead, a mannitol bead, a silica bead, a tartaric acid pellet, a wax based pellet, and the like.
As used herein, the term "extended release," are used to define a release profile to effect delivery of guanfacine over an extended period of time, as being between about 60 minutes to about 2, 4, 6, 8, 12 or 24 hours. Extended release includes sustained release, controlled release, multiphase release, delayed release, pulsatile release, chrono release and the like.
When present in an extended release form, the composition comprises:
(i) cores comprising guanfacine and a release-controlling agent; and
(ii) a pharmaceutically acceptable carrier.
The cores may comprise guanfacine as powder, granules, and pellets.
Alternatively, guanfacine may be layered over an inert particle to form a core.
Alternatively, guanfacine may be present as a complex with a suitable complexing agent such as cyclodextrin, ion-exchange resins.
The core is in the form of a bead, pellet, granule, and spheroid or like. The release-controlling agent is selected from the group comprising a pH- dependent release-controlling agent, a pH-independent release-controlling agent or mixtures thereof.
Suitable examples of pH-dependent release-controlling agents are selected from the group comprising acrylic copolymers such as methacrylic acid and methyl methacrylate copolymers, e.g., Eudragit® L 100 and Eudragit® S 100, methacrylic acid and ethyl acrylate copolymers, e.g., Eudragit® L 100-55 and Eudragit® L 30 D-55, dimethylaminoethyl methacrylate and butyl methacrylate and methyl methacrylate copolymers e.g., Eudragit® E 100, Eudragit® E PO, methyl acrylate and methacrylic acid and octyl acrylate copolymers, styrene and acrylic acid copolymers, butyl acrylate and styrene and acrylic acid copolymers, and ethylacrylate-methacrylic acid copolymer;
cellulose acetate phthalate; cellulose acetate succinates; hydroxyalkyl cellulose phthalates such as hydroxypropylmethyl cellulose phthalate; hydroxyalkyl cellulose acetate succinates such as hydroxypropylmethyl cellulose acetate succinate; vinyl acetate phthalates; vinyl acetate succinate; cellulose acetate trimelliate; polyvinyl derivatives such as polyvinyl acetate phthalate, polyvinyl alcohol phthalate, polyvinyl butylate phthalate, and polyvinyl acetoacetal phthalate; zein; shellac; and mixtures thereof.
Suitable examples of pH-independent release-controlling agents ar e selected from the group comprising cellulosic polymers such as ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and carboxy methylcellulose; acrylic copolymers such as methacrylic acid copolymers, e.g., Eudragit® RS, Eudragit® RL, Eudragit® NE 30 D;; polyethylene derivatives e.g., polyethylene glycol and polyethylene oxide; polyvinyl alcohol; polyvinyl acetate; gums e.g., guar gum, locust bean gum, tragacanth, carrageenan, alginic acid, gum acacia, gum arabic, gellan gum, and xanthan gum; triglycerides; waxes, e.g., Compritol®, Lubritab®, and Gelucires®; lipids; fatty acids or their salts/derivatives; polyvinyl polymers; a mixture of polyvinyl acetate and polyvinyl pyrrolidone, e.g., Kollidon® SR; and mixtures thereof. In particular, the pll-independent polymer used in the present invention is ethyl cellulose.
The coating additives used in the present invention are selected from the group comprising plasticizers, opacifiers, anti-tacking agents, coloring agents, or combinations thereof. Suitable plasticizers are selected from the group comprising triethyl citrate, dibutylsebacate, triacetin, acetylated triacetin, tributyl citrate, glyceryl tributyrate, diacetylated monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyl oxalate, diethyl phthalate, diethyl malate, diethyl fumarate, dibutyl succinate, diethyl malonate, dioctyl phthalate, and mixtures thereof.
Suitable opacifiers are selected from the group comprising titanium dioxide, manganese dioxide, iron oxide, silicon dioxide, and mixtures thereof.
Suitable anti-tacking agents are selected from the group comprising talc, magnesium stearate, calcium stearate, stearic acid, silica, glyceryl monostearate, and mixtures thereof.
Suitable coloring agents are selected from the group consisting of FD&C (Federal Food, Drug and Cosmetic Act) approved coloring agents; natural coloring agents; natural juice concentrates; pigments such as iron oxide, titanium dioxide, and zinc oxide; and mixtures thereof.
Suitable solvents used for granulation or for forming a solution or dispersion for coating are selected from the group comprising water, ethanol, methylene chloride, isopropyl alcohol, acetone, methanol, and combinations thereof.
The diameter of the cores comprising guanfacine and a release-controlling agent has a ds>o value of less than about 1.5 mm. More particularly, dgo value is less than 1.2 mm. It is desirable to keep the diame ter of the cores within the specified size so as to avoid sedimentation of the cores, grittiness in the mouth and thereby rendering the composition more acceptable. The diameter of the cores is measured according to known methods, such as using Camsizer.
As used herein, the term "dw value," means at least 90% of the cores have volume diameter in the specified range when measured by a suitable method, for example, Camsizer.
Pharmaceutically acceptable carrier, constitutes the liquid part of the composition and comprises one or more of liquid adjuvants and other pharmaceutically acceptable excipients. Suitable liquid adjuvants comprise water. It may optionally comprise a co-solvent, for example, propylene glycol, glycerol, sorbitol, and the like, to assist solubilization and incorporation of various water-insoluble ingredients, such as flavoring oils and the like, into the composition.
In certain embodiment, other pharmaceutically acceptable excipients in the carrier are selected from the group comprising acids, osmogents, buffering agents, suspending agents, glidants, sweetening agents, flavors, colorants, anti-caking agents, wetting agents, preservatives, antioxidants, chelating agents, binders, viscosity modifiers, emulsifiers, and combinations thereof.
Suitable acids are selected from the group comprising organic acids, inorganic acids or mixtures thereof. Organic acids are selected from the group comprising citric acid, fumaric acid, tartaric acid, oxalic acid, succinic acid, adipic acid, phthalic acid, acetic acid, alginic acid, ascorbic acid, aspartic acid, benzoic acid, cyclamic acid, erythorbic acid, glutamic acid hydrochloride, lactic acid, maleic acid, methacrylic acid, oleic acid, palmitic acid, sorbic acid, stearic acid, and combinations thereof. Inorganic acids are selected from the group comprising hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, perchloric acid, and combinations thereof. Citric acid, fumaric acid, tartaric acid, ascorbic acid, benzoic acid, and hydr ochloric acid are preferably used.
As used herein, the term "osmogents", refers to all pharmaceutically acceptable inert water-soluble compounds that can imbibe or dissolve in water and/or aqueous biological fluids. Suitable examples of osmogents or pharmaceutically acceptable inert water-soluble compounds are selected from the group comprising carbohydrates such as xylitol, mannitol, sorbitol, arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, dextrose and raffmose; water-soluble salts of inorganic acids such as magnesium chloride, magnesium sulfate, potassium sulfate, lithium chloride, sodium chloride, potassium chloride, lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydr ogen phosphate, lithium dihydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, and sodium phosphate tribasic; water-soluble salts of organic acids such as sodium acetate, potassium acetate, magnesium succinate, sodium benzoate, sodium citrate, and sodium ascorbate; water-soluble amino acids such as glycine, leucine, alanine, methionine; urea or its derivatives; propylene glycol; glycerin; polyethylene oxide, xanthan gum, hydroxypropylmethyl cellulose; and mixtures thereof. Particularly, the osmogents used in the present invention are xylitol, mannitol, glucose, lactose, sucrose, and sodium chloride. Particularly, the osmogents used in the present invention are xylitol, mannitol, glucose, lactose, sucrose, and sodium chloride.
Suitable buffering agents are selected from the group comprising hydrochloric acid, citric acid, sodium citrate, potassium citrate, acetate buffer, sodium acetate trihydrate, potassium dihydrogen orthophosphate, trisodium hydrogen orthophosphate, sodium dihydrogen orthophosphate, disodium hydrogen orthophosphate, and mixtures thereof.
Suitable suspending agents are selected from the group comprising cellulose derivatives such as co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose and its salts/derivatives, and microcrystalline cellulose; carbomers; gums such as locust bean gum, xanthan gum, tragacanth gum, arabinogalactan gum, agar gum, gellan gum, guar gum, apricot gum, karaya gum, sterculia gum, acacia gum, gum arabic, and carrageenan; pectin; dextran; gelatin; polyethylene glycols; polyvinyl compounds such as polyvinyl acetate, polyvinyl alcohol, and polyvinyl pyrrolidone; sugar alcohols such as xylitol and mannitol; colloidal silica; and mixtures thereof. The co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium have been marketed under the trade names Avicel® RC-501, Avicel® RC-581, Avicel® RC-591, and Avicel®CL-611.
Suitable glidants are selected from the group comprising silica, calcium silicate, magnesium silicate, colloidal silicon dioxide, corn starch, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, hydrogenated vegetable, and mixtures thereof.
Suitable sweetening agents are selected from the group comprising saccharine or its salts such as sodium, potassium, or calcium, cyclamate or its salt, aspartame, alitame, acesulfame or its salt, stevioside, glycyrrhizin or its derivatives, sucralose, and mixtures thereof.
Suitable flavors are selected from the group comprising peppermint, grapefruit, orange, lime, lemon, mandarin, pineapple, strawberry, raspberry, mango, passion fruit, kiwi, apple, pear, peach, apricot, cherry, grape, banana, cranberry, blueberry, black currant, red currant, gooseberry, lingon berries, cumin, thyme, basil, camille, valerian, fennel, parsley, chamomile, tarragon, lavender, dill, bargamot, salvia, aloe vera balsam, spearmint, eucalyptus, and combinations thereof.
Suitable coloring agents are selected from the group comprising dyes, natural coloring agents or pigments, approved for use under Federal Food, Drug and Cosmetic Act.
Suitable anti-caking agents are selected from the group comprising colloidal silicon dioxide, tribasic calcium phosphate, powdered cellulose, magnesium trisilicate, starch, and mixtures thereof.
Suitable wetting agents are selected from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, and combinations thereof. Suitable examples of wetting agents are sodium lauryl sulphate; cetrimide; polyethylene glycols;
polyoxyethylene-polyoxypropylene block copolymers such as poloxamers; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid esters such as sorbitan monostearate; polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate; polyethylene glycol fatty acid ester such as polyoxyethylene monostear ate; polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil; and mixtures thereof.
Suitable preservatives are selected from the group comprising parabens such as methyl, ethyl, propyl, and butyl p-hydroxybenzoic acid esters, alkyl hydroxybenzoates, sorbic acid or a salt thereof, benzoic acid or a salt thereof, salts of edetate (also known as salts of ethylenediaminetetraacetic acid or EDTA, such as disodium edetate), benzalkonium chloride, and mixtures thereof.
Suitable antioxidants are selected from the group comprising butylated hydroxytoluene (BUT), butylated hydroxyanisole (BHA), sodium metabisulfite, ascorbic acid, propyl gallate, thiourea, tocopherols, beta-carotene, and mixtures thereof.
Suitable chelating agents are selected from the group comprising ethylenediamine tetraacetic acid (EDTA) and its salts, such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, and mixtures thereof.
Suitable binders are selected from the group comprising polyvinyl pyrrolidone, starch, pregelatinized starch, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, gums, acrylate polymers, and mixtures thereof.
Suitable viscosity modifiers are selected from the group comprising chitosan, acacia, alginic acid bentonite, carbomers, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethyl cellulose, glycerin, gelatin guar gum, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, any other suitable cellulose-based component, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, starch, sodium starch glycolate, starch tragacanth, xanthan gum, and mixtures thereof.
Suitable emulsifiers include, but are not limited to natural emulsifier, an anionic emulsifier or a nonionic emulsifier. These include, but are not limited to, sodium dodecyl sulfate, sodium octadecyl sulfate, sorbitol anhydrate, tween, and mixtures thereof.
The viscosity of the pharmaceutically acceptable carrier ranges from about 300 cps to about 15,000 cps. Preferably, the viscosity of the carrier ranges from about 500 cps to about 10,000 cps, More preferably, the viscosity of the carrier ranges from about 500 cps to about 7,000 cps. The viscosity of the carrier of the present invention is measured by using a Brookfield Viscometer having a # 3 spindle rotating at 20 rpm at 25 °C.
The amounts of each excipient can readily be determined or ascertained by the person skilled in the art.
When the liquid composition is an extended release composition, it may additionally comprise an immediate release component for biphasic or pulsatile type of release. Immediate release component may help in providing an immediate therapeutic effect which could be subsequently followed by an extended therapeutic effect over a longer duration of time. In one example, immediate release component may be present in the form a powder, pellets, beads, spheroids or granules of guanfacine in the carrier. Alternatively, the immediate release component may be present in the form of an immediate release coating of guanfacine over the extended release coated cores.
Alternatively, the immediate release component of guanfacine may be present in form of guanfacine-resin complexes.
The invention also provides for methods of making the compositions described herein by usual methods well known in the art. Ready-to use liquid compositions may be prepared by the conventional processes comprising dissolving an amount of guanfacine and any other excipients into the pharmaceutically acceptable carrier.
Alternatively, the process comprises preparing cores comprising guanfacine and optionally one or more other pharmaceutically acceptable excipients. These guanfacine containing cores are then coated with a suitable polymer for immediate release or extended release by usual coating techniques. These coated cores are then dispersed in the pharmaceutically acceptable carrier to form ready-to-use liquid composition.
Reconstituted liquid compositions of the present invention may be prepared by the process comprising the steps of forming powder, granules or pellets as dry powder by conventional processes.
The process also includes forming complexes of guanfacine with ion-exchange resins, compri sing loading a plurality of resin particles with guanfacine to form drug-resin particles. These particles may optionally be further coated with immediate release or extended release coating using conventional techniques. Methods of loading drugs onto resin particles are generally known in the art.
The ready-to-use liquid compositions of the present invention may be packaged in a suitable package such as a bottle. The dry powder for reconstitution may be packaged in a suitable package such as a bottle or a sachet. Further, the sachet can be filled as a unit dose or a multi dose sachet. The present invention further includes a co-package or a kit comprising two components, wherein one package or one component comprises a dry powder and another package or another component comprises the pharmaceutically acceptable carrier. Alternatively, a twin chamber pack with two chambers can be used. In this case, one chamber comprises a powder for suspension and another chamber comprises the carrier.
The invention also provides for various methods of treatment using the compositions described herein. In a particular embodiment, the invention provides for methods of treating ADHD or hypertension comprising administering an effective amount of any of the composition described herein, wherein the composition is meant for immediate release or extended release or combination of both. The invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
Table 1; pH dependent degradation profile (Guanfacine hydrochloride)-solution state stability
As can be seen from the above Table 1, the assay values of guanfacine are substantially decreasing over time at high pH values, clearly indicating decreased stability of guanfacine at high pH. On the other hand, no major changes in assay values of guanfacine were observed in acidic conditions over time, indicating guanfacine is stable at lower pH values.
Examples 1-2; Comparative compositions of guanfacine
Procedure:
Guanfacine hydrochloride, xylitol, citric acid (in Example 1) were mixed in water to form liquid compositions.
Stability studies
The compositions prepared as per Example 1 and Example 2 (Comparative Example) were stored at room temperature and the samples were analyzed after 3 days and 7 days. Stability results are represented in Table 2 below. Table 2: Stability data of compositions prepared as per Example 1 and Example 2
As seen from the above Table 2, it is observed that the amounts of impurity 2, 6- dichlorophenyl acetic acid and total related substances was significantly reduced in composition having an acid as compared to the composition without an acid. Hence, it is clear that inclusion of an acid enhanced the stability of guanfacine.
Examples 3-5: Compositions of guanfacine with different acids
Procedure:
Guanfacine hydrochloride, suitable acid (fumaiic/tartaric/citric acids) were mixed in water to form liquid compositions.
Stability studies
The compositions prepared as per Examples 3-5 were stored at room temperature and the samples were analyzed after 30 days. Stability results are represented in Table 3 below. Table 3- Stability data of compositions prepared as per Examples 3-5
As seen from the above Table 3, equivalent stability results have been obtained with all the three studied acids i.e. fumaric acid, tartaric acid and citric acid.
Examples 6-8: Guanfacine extended release powder for suspension compositions
Procedure:
1. Citric acid, mannitol, hydroxypropylmethyl cellulose, guanfacine hydrochloride were dissolved in purified water. 2. Microcrystalline cellulose spheres were coated with the solution of step 1.
3. Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
4. The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
5. Microcrystalline cellulose - sodium carboxymethyl cellulose, xanthan gum, colloidal silicon dioxide, sucralose, xylitol, strawberry flavor, citric acid, methyl/ propyl paraben (if present) were mixed in purified water to form the pharmaceutically acceptable carrier.
6. The extended release powder for suspension and the pharmaceutically acceptable carrier were separately packed in a twin chamber pack.
Stability studies
The extended release powder for suspension compositions prepared as per Examples 7 and 8 were stored at 40°C/ 75%RH for 3 months and 1 month respectively. Thereafter, the powder for suspension was reconstituted with the carrier and the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The initial levels of impurities/ related substances and levels after 3 months/ 1 month are represented in Table 4 below.
Table 4- Stability data of the reconstituted liquid compositions prepared as per Examples 7-8
In-vitro studies
The extended release powder for suspension prepared as per Examples 6 and 8 was reconstituted with the carrier and the in-vitro dissolution was determined for 4 mg dose at day 0 using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C. The results of the release studies are represented in Table 5. Table 5 - Percentage (%) of guanfacine release from reconstituted compositions prepared as per Examples 6 and 8 in 900 inL hydrochloric acid buffer pH 2.2, USP type II, 75 rpm
Examples 9-12: Guanfacine extended release powder for suspension compositions
Procedure:
Citric acid, mannitol, hydroxypropylmethyl cellulose, guanfacine hydrochloride dissolved in purified water. 2. Microcrystalline cellulose spheres were coated with the solution of step 1.
3. Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
4. The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
5. Xylitol and citric acid were mixed in purified water to form the pharmaceutically acceptable carrier,
6. The extended release powder for suspension was reconstituted with the pharmaceutically acceptable carrier and packed in a suitable container.
Stability studies
The compositions prepared as per Examples 9-12 were stored at room temperature for 30 days. After 30 days, the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The results are represented in Table 6 below.
Table 6- Stability data of the reconstituted liquid compositions prepared as per Examples 9-12
In-vitro studies
The powder for suspension compositions prepared as per Examples 9-1 1 was stored for 10 days/ 30 days. After 10 days/ 30 days, the in-vitro dissolution was determined for 4 mg dose using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C. The results of the release studies are represented in Table 7 below. Table 7- Percentage (%) of guanfacine release from reconstituted liquid compositions prepared as per Examples 9-11 in hydrochloric acid buffer pH 2.2, USP type II, 75 rpm, 900ml
Examples 13-14: Guanfacine extended release powder for suspension compositions
Procedure:
1. Citric acid, mannitol, hydroxypropyl methylcellulose, guanfacine hydrochloride were dissolved in purified water.
2. Microcrystalline cellulose spheres were coated with the solution of step 1.
3. Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and
purified water.
4. The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
5. Microcrystalline cellulose - sodium carboxymethyl cellulose, xylitol, citric acid, xanthan gum, colloidal silicon dioxide, sucralose, strawberry flavor, methyl paraben and propyl paraben were mixed in purified water to form the pharmaceutically acceptable carrier.
6. The extended release powder for suspension and the pharmaceutically acceptable carrier were separately packed in a twin chamber pack.
Stability studies
The extended release powder for suspension composition prepared as per Example 14 was stored at 40°C/75%RH for one month. After one month, the powder for suspension was reconstituted with the carrier and the amounts of impurity 2, 6-dichlorophenyl acetic acid and total related substances was determined. The initial levels of impurities/ related substances and levels after 1 month are represented in Table 8 below.
Table 8- Stability data of reconstituted liquid compositions prepared as per Example 14
In-vitro studies
The extended release powder for suspension prepared as per Example 14 was stored at 40°C/75%RH for one month. After one month, the in-vitro dissolution was determined for 4 mg dose using USP type II apparatus at 75 rpm, in 900 mL of hydrochloric acid buffer with pH 2.2 at 37°C. The results of the initial release studies and after 1 month are represented in Table 9 below.
Table 9: Percentage (%) of guanfacine release from extended release powder for suspension prepared as per Example 14 in 900mL of hydrochloric acid buffer, pH 2.2. USP type II. 75 rpm
Core size measurements
The sizes of the guanfacine layered cores and the extended release coated cores prepared as per Example 14 were measured by Camsizer and the results are provided in Table 10 below- Table 10- Core sizes
Viscosity measurements
Viscosity of the carrier prepared as per Example 14 was measured by Brookfield viscometer. The values are provided in Table 11 below. Table 11: Viscosity measurements
Example 15: Guanfacine extended release powder for suspension compositions
Procedure:
1. Citric acid, Eudragit®L 100-55, triethyl citrate, talc, guanfacine hydrochloride were dispersed in a mixture of acetone and purified water. 2. Microcrystalline cellulose spheres were coated with the dispersion of step 1.
3. Ethyl cellulose and dibutyl sebacate were dispersed in a mixture of acetone and purified water.
4. The drug layered cores of step 2 were coated with the coating dispersion of step 3 to form extended release powder for suspension.
5. Microcrystalline cellulose - sodium carboxymethyl cellulose, xylitol, citric acid, xanthan gum, colloidal silicon dioxide, sucralose, strawberry flavor, methyl paraben and propyl paraben were mixed in purified water to form the pharmaceutically acceptable carrier.
6. The extended release powder for suspension and the pharmaceutically acceptable carrier were separately packed in a twin chamber pack.
Procedure:
1. Dissolve citric acid, mannitol, hydroxypropyl methyl cellulose, and guanfacine hydrochloride in purified water under stirring to get clear solution.
2. Spray the solution obtained from step 1 onto microcrystalline cellulose spheres. 3. Mix microcrystalline cellulose - sodium carboxymethyl cellulose, xanthan gum, colloidal silicon dioxide, sucralose, xylitol, strawberry flavor, citric acid, methyl paraben, propyl paraben under stirring to make a uniform dispersion in purified water to form the pharmaceutically acceptable carrier.
4. Pack separately drug layered cores and the carrier in a twin chamber pack.

Claims

We claim:
1. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
2. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition comprises guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/niL of the composition.
3. The oral liquid composition of claim 2, wherein the composition comprises guanfacine in a concentration from about 1.0 mg/mL to 7.0 mg/mL of the composition.
4. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a stable composition.
5. The oral liquid composition of claim 4, wherein the composition comprises less than about 1.0% w/w of 2, 6-dichlorophenyl acetic acid as an impurity.
6. The oral liquid composition of claim 5, wherein the composition comprises less than about 0.7% w/w of 2, 6-dichlorophenyl acetic acid as an impurity.
7. The oral liquid composition of claim 4, wherein the composition comprises less than about 3.0% w/w of total related substances.
8. The oral liquid composition of claim 7, wherein the composition comprises less than about 2.0% w/w of total related substances.
9. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition has a pH of less than about 6.8,
10. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein the composition is a ready-to-use liquid composition or a reconstituted liquid composition.
11. The oral liquid composition of claim 10, wherein the ready-to-use liquid composition comprises a solution, a suspension, a syrup, a concentrate, an elixir, or an emulsion.
12. The oral liquid composition of claim 10, wherein the reconstituted liquid composition comprises a solution and/or a suspension reconstituted from powder comprising granules, pellets, or beads.
13. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an immediate release form.
14. The oral liquid composition of claim 13, wherein guanfacine is present as powder, pellets, granules, beads.
15. The oral liquid composition of claim 13, wherein guanfacine is present as guanfacine- resin complex.
16. The oral liquid composition of claim 13, wherein guanfacine is layered over inert cores.
17. An oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier, wherein guanfacine is present in an extended release form.
18. The oral liquid composition of claim 17, wherein the composition comprises:
(i) cores comprising guanfacine and a release-controlling agent; and
(ii) a pharmaceutically acceptable carrier.
19. The oral liquid composition of claim 18, wherein guanfacine is present in the core or layered over an inert particle to form a core.
20. The oral liquid composition of claim 18, wherein release-controlling agent is present in the core or coated over the guanfacine core or both.
21. The oral liquid composition of claim 20, wherein the release-controlling agent is selected from the group consisting of a pH-dependent release-controlling agent, a pH- independent release-controlling agent, and mixtures thereof.
22. The oral liquid composition of claim 21, wherein the pH-dependent release- controlling agent is selected from the group consisting of acrylic copolymers, methacrylic acid and ethyl acrylate copolymers; cellulosic polymers; vinyl polymers; polyvinyl derivatives; zein; shellac; and combinations thereof.
23. The oral liquid composition of 21 , wherein the pH-independent release-controlling agent is selected from the group consisting of cellulosic polymers; acrylic copolymers; polyethylene derivatives; polyvinyl alcohol; polyvinyl acetate; gums; triglycerides; waxes; lipids; fatty acids or their salts/derivatives; polyvinyl polymers; polyvinyl acetate and polyvinyl pyrrolidone mixtures; and combinations thereof.
24. The oral liquid composition of claim 1 8, wherein the core further comprises pharmaceutically acceptable excipients selected from the group consisting of acids, osmogents, binders, glidants, and combinations thereof .
25. The oral liquid composition of claim 17, wherein the composition further comprises guanfacine in an immediate release form.
26. The oral liquid composition of claim 1, wherein the pharmaceutically acceptable carrier comprise one or more liquid adjuvants and other pharmaceutically acceptable excipients.
27. The oral liquid composition of claim 26, wherein the other pharmaceutically acceptable excipients are selected from the group comprising acids, osmogents, buffering agents, suspending agents, glidants, sweetening agents, flavors, colorants, anti-caking agents, wetting agents, preservatives, antioxidants, chelating agents, binders, viscosity modifiers, emulsifiers and combinations thereof.
28. A method of treating Attention Deficit Hyperactivity Disorder or Hypertension by administering an oral liquid composition comprising guanfacine in a pharmaceutically acceptable carrier.
29. A method of treating Attention Deficit Hyperactivity Disorder or Hypertension, wherein the oral liquid composition of claim 28 is administered once daily.
EP16789380.9A 2015-05-01 2016-05-02 Oral liquid compositions of guanfacine Pending EP3288549A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2015/053209 WO2015166473A1 (en) 2014-05-01 2015-05-01 Extended release suspension compositions
US15/133,826 US20160228379A1 (en) 2014-05-01 2016-04-20 Extended release suspension compositions
PCT/IB2016/052485 WO2016178131A1 (en) 2015-05-01 2016-05-02 Oral liquid compositions of guanfacine

Publications (2)

Publication Number Publication Date
EP3288549A1 true EP3288549A1 (en) 2018-03-07
EP3288549A4 EP3288549A4 (en) 2020-01-15

Family

ID=61024258

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16789380.9A Pending EP3288549A4 (en) 2015-05-01 2016-05-02 Oral liquid compositions of guanfacine

Country Status (2)

Country Link
EP (1) EP3288549A4 (en)
WO (1) WO2016178131A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2017001332A (en) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Dual-chamber pack.
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
MX2012014432A (en) * 2010-06-11 2013-05-20 Shire Llc Combination therapy with lisdexamphetamine and extended release guanfacine.
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
EP2796133A1 (en) * 2013-04-26 2014-10-29 Salmon Pharma GmbH Sustained release guanfacine HCl formulation
WO2015166473A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions

Also Published As

Publication number Publication date
EP3288549A4 (en) 2020-01-15
WO2016178131A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
US9962345B2 (en) Oral liquid compositions of guanfacine
US9962336B2 (en) Extended release suspension compositions
JP5634882B2 (en) Drug delivery system comprising weakly basic drug and organic acid
ES2746884T3 (en) Pharmaceutical formulations for the treatment of overactive bladder
EP3445349A1 (en) Extended release suspension compositions
US10258583B2 (en) Extended release liquid compositions of guanfacine
WO2016178131A1 (en) Oral liquid compositions of guanfacine
EP2961383B1 (en) Suspension for oral administration comprising amorphous tolvaptan
US11504345B2 (en) Extended release liquid compositions of metformin
WO2017182852A1 (en) Extended release liquid compositions of guanfacine
US20160228360A1 (en) Extended release liquid compositions of metformin
ES2852899T3 (en) Stabilized Molindone Formulations
EP3288539A1 (en) Extended release liquid compositions of metformin
ES2860694T3 (en) Sustained-release pharmaceutical composition containing rivastigmine
EP3445350A1 (en) Extended release liquid compositions of guanfacine
ES2896150T3 (en) Guaifenesin Extended-Release Liquid Compositions
US9498441B2 (en) Nitazoxadine composition and process to prepare same
WO2022147183A1 (en) Pharmaceutical extended release suspensions of riociguat

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031165000

Ipc: A61K0009100000

A4 Supplementary search report drawn up and despatched

Effective date: 20191217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101ALI20191211BHEP

Ipc: A61K 9/50 20060101ALI20191211BHEP

Ipc: A61K 31/165 20060101ALI20191211BHEP

Ipc: A61K 9/10 20060101AFI20191211BHEP

Ipc: A61K 47/12 20060101ALI20191211BHEP

Ipc: A61K 9/00 20060101ALI20191211BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220721

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230424